Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Geoffrey T. Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas F. Gajewski, Bartosz Chmielowski, Brent A. Hanks, Yufan Zhao, Robert C. Newton, Janet Maleski, Lance Leopold, Jeffrey S. Weber

ABSTRACT

BACKGROUND: Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, in advanced melanoma (NCT01604889). METHODS: Only the phase 1, open-label portion of the study was conducted, per the sponsor's decision to terminate the study early based on the changing melanoma treatment landscape favoring exploration of programmed cell death protein 1 (PD-1)/PD-ligand 1 inhibitor-based combination strategies. Such decision was not related to the safety of epacadostat plus ipilimumab. Patients received oral epacadostat (25, 50, 100, or 300 mg twice daily [BID]; 75 mg daily [50 mg AM, 25 mg PM]; or 50 mg BID intermittent [2 weeks on/1 week off]) plus intravenous ipilimumab 3 mg/kg every 3 weeks. RESULTS: Fifty patients received ≥1 dose of epacadostat. As of January 20, 2017, 2 patients completed treatment and 48 discontinued, primarily because of adverse events (AEs) and disease progression (n = 20 each). Dose-limiting toxicities occurred in 11 patients (n = 1 each with epacadostat 25 mg BID, 50 mg BID intermittent, 75 mg daily; n = 4 each with epacadostat 50 mg BID, 300 mg BID). The most common immune-related treatment-emergent AEs included rash (50%), alanine aminotransferase elevation (28%), pruritus (28%), aspartate aminotransferase elevation (24%), and hypothyroidism (10%). Among immunotherapy-naive patients (n = 39), the objective response rate was 26% by immune-related response criteria and 23% by Response Evaluation Criteria in Solid Tumors version 1.1. No objective response was seen in the 11 patients who received prior immunotherapy. Epacadostat exposure was dose proportional, with clinically significant IDO1 inhibition at doses ≥25 mg BID. CONCLUSIONS: When combined with ipilimumab, epacadostat ≤50 mg BID demonstrated clinical and pharmacologic activity and was generally well tolerated in patients with advanced melanoma. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01604889 . Registration date, May 9, 2012, retrospectively registered. More... »

PAGES

80

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-019-0562-8

DOI

http://dx.doi.org/10.1186/s40425-019-0562-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112899763

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30894212


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "MedStar Georgetown University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411663.7", 
          "name": [
            "Donald A. Adam Melanoma and Skin Cancer Research Center of Excellence, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA", 
            "Present Address: Lombardi Comprehensive Cancer Center, Medstar-Georgetown University Hospital, 3800 Reservoir Road NW, Podium A, 20007, Washington, DC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gibney", 
        "givenName": "Geoffrey T.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Angeles Clinic and Research Institute", 
          "id": "https://www.grid.ac/institutes/grid.488730.0", 
          "name": [
            "Melanoma and Skin Cancers Center, The Angeles Clinic and Research Institute, 11818 Wilshire Blvd, Suite #200, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamid", 
        "givenName": "Omid", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mount Sinai Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.410396.9", 
          "name": [
            "Division of Hematology & Oncology, Mount Sinai Medical Center, 4306 Alton Rd, Miami Beach, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lutzky", 
        "givenName": "Jose", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Temple University Health System", 
          "id": "https://www.grid.ac/institutes/grid.412530.1", 
          "name": [
            "Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Olszanski", 
        "givenName": "Anthony J.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital of the University of Pennsylvania", 
          "id": "https://www.grid.ac/institutes/grid.411115.1", 
          "name": [
            "Division of Hematology Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mitchell", 
        "givenName": "Tara C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Hematology/Oncology, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gajewski", 
        "givenName": "Thomas F.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California Los Angeles", 
          "id": "https://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Jonsson Comprehensive Medical Center, University of California, Los Angeles, 10945 Le Conte Ave #2339, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chmielowski", 
        "givenName": "Bartosz", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Medicine, Duke University Medical Center, 20 Duke Medicine Cir, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanks", 
        "givenName": "Brent A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Incyte (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417921.8", 
          "name": [
            "Incyte Corporation, 1801 Augustine Cutoff, Wilmington, DE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhao", 
        "givenName": "Yufan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Incyte (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417921.8", 
          "name": [
            "Incyte Corporation, 1801 Augustine Cutoff, Wilmington, DE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Newton", 
        "givenName": "Robert C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Incyte (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417921.8", 
          "name": [
            "Incyte Corporation, 1801 Augustine Cutoff, Wilmington, DE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maleski", 
        "givenName": "Janet", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Incyte (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417921.8", 
          "name": [
            "Incyte Corporation, 1801 Augustine Cutoff, Wilmington, DE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Leopold", 
        "givenName": "Lance", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New York University Langone Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.240324.3", 
          "name": [
            "Donald A. Adam Melanoma and Skin Cancer Research Center of Excellence, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA", 
            "Present Address: Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weber", 
        "givenName": "Jeffrey S.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30366-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001468571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cellimm.2014.02.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001542971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2051-1426-2-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002294525", 
          "https://doi.org/10.1186/2051-1426-2-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.immuni.2013.07.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006498518"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2009-09-246124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009595417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)60958-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012632588"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1503093", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014234053"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015972513", 
          "https://doi.org/10.1038/nm934"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015972513", 
          "https://doi.org/10.1038/nm934"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra041867", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016818264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0143080", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019103667"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-015-0094-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022743938", 
          "https://doi.org/10.1186/s40425-015-0094-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1504030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024843336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-1624", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028571226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2326-6066.cir-14-0137", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031443287"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci31178", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032110459"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4049/jimmunol.1100164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033755558"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/10408363.2011.599831", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034859605"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.celrep.2015.08.077", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034973964"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2011.09.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036514939"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.28927", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039147819"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci21583", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041748772"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1305133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042841008"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-09-0628", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044405906"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1003466", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052212829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-16-2272", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063225692"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000492849", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106286757"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2018.36.15_suppl.108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106714265"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, in advanced melanoma (NCT01604889).\nMETHODS: Only the phase 1, open-label portion of the study was conducted, per the sponsor's decision to terminate the study early based on the changing melanoma treatment landscape favoring exploration of programmed cell death protein 1 (PD-1)/PD-ligand 1 inhibitor-based combination strategies. Such decision was not related to the safety of epacadostat plus ipilimumab. Patients received oral epacadostat (25, 50, 100, or 300 mg twice daily [BID]; 75 mg daily [50\u2009mg AM, 25 mg PM]; or 50 mg BID intermittent [2\u2009weeks on/1\u2009week off]) plus intravenous ipilimumab 3 mg/kg every 3 weeks.\nRESULTS: Fifty patients received \u22651 dose of epacadostat. As of January 20, 2017, 2 patients completed treatment and 48 discontinued, primarily because of adverse events (AEs) and disease progression (n\u2009=\u200920 each). Dose-limiting toxicities occurred in 11 patients (n\u2009=\u20091 each with epacadostat 25 mg BID, 50 mg BID intermittent, 75 mg daily; n\u2009=\u20094 each with epacadostat 50 mg BID, 300 mg BID). The most common immune-related treatment-emergent AEs included rash (50%), alanine aminotransferase elevation (28%), pruritus (28%), aspartate aminotransferase elevation (24%), and hypothyroidism (10%). Among immunotherapy-naive patients (n\u2009=\u200939), the objective response rate was 26% by immune-related response criteria and 23% by Response Evaluation Criteria in Solid Tumors version 1.1. No objective response was seen in the 11 patients who received prior immunotherapy. Epacadostat exposure was dose proportional, with clinically significant IDO1 inhibition at doses \u226525\u2009mg BID.\nCONCLUSIONS: When combined with ipilimumab, epacadostat \u226450\u2009mg BID demonstrated clinical and pharmacologic activity and was generally well tolerated in patients with advanced melanoma.\nTRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01604889 . Registration date, May 9, 2012, retrospectively registered.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s40425-019-0562-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "name": "Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma", 
    "pagination": "80", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9ae17cccc8d9657d682c59e3f1f732d13e0d9e9b0e1fd003473c149bdc131746"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30894212"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101620585"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-019-0562-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112899763"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-019-0562-8", 
      "https://app.dimensions.ai/details/publication/pub.1112899763"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000370_0000000370/records_46754_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs40425-019-0562-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0562-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0562-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0562-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0562-8'


 

This table displays all metadata directly associated to this object as RDF triples.

254 TRIPLES      21 PREDICATES      57 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-019-0562-8 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author Nfef5b798b6c34c90a79962c20d3dac03
4 schema:citation sg:pub.10.1038/nm934
5 sg:pub.10.1186/2051-1426-2-3
6 sg:pub.10.1186/s40425-015-0094-9
7 https://doi.org/10.1002/ijc.28927
8 https://doi.org/10.1016/j.cellimm.2014.02.005
9 https://doi.org/10.1016/j.celrep.2015.08.077
10 https://doi.org/10.1016/j.ejca.2008.10.026
11 https://doi.org/10.1016/j.ejca.2011.09.007
12 https://doi.org/10.1016/j.immuni.2013.07.012
13 https://doi.org/10.1016/s0140-6736(14)60958-2
14 https://doi.org/10.1016/s1470-2045(16)30366-7
15 https://doi.org/10.1056/nejmoa1003466
16 https://doi.org/10.1056/nejmoa1305133
17 https://doi.org/10.1056/nejmoa1503093
18 https://doi.org/10.1056/nejmoa1504030
19 https://doi.org/10.1056/nejmra041867
20 https://doi.org/10.1158/1078-0432.ccr-09-1624
21 https://doi.org/10.1158/1078-0432.ccr-16-2272
22 https://doi.org/10.1158/1535-7163.mct-09-0628
23 https://doi.org/10.1158/2326-6066.cir-14-0137
24 https://doi.org/10.1159/000492849
25 https://doi.org/10.1172/jci21583
26 https://doi.org/10.1172/jci31178
27 https://doi.org/10.1182/blood-2009-09-246124
28 https://doi.org/10.1200/jco.2018.36.15_suppl.108
29 https://doi.org/10.1371/journal.pone.0143080
30 https://doi.org/10.3109/10408363.2011.599831
31 https://doi.org/10.4049/jimmunol.1100164
32 schema:datePublished 2019-12
33 schema:datePublishedReg 2019-12-01
34 schema:description BACKGROUND: Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, in advanced melanoma (NCT01604889). METHODS: Only the phase 1, open-label portion of the study was conducted, per the sponsor's decision to terminate the study early based on the changing melanoma treatment landscape favoring exploration of programmed cell death protein 1 (PD-1)/PD-ligand 1 inhibitor-based combination strategies. Such decision was not related to the safety of epacadostat plus ipilimumab. Patients received oral epacadostat (25, 50, 100, or 300 mg twice daily [BID]; 75 mg daily [50 mg AM, 25 mg PM]; or 50 mg BID intermittent [2 weeks on/1 week off]) plus intravenous ipilimumab 3 mg/kg every 3 weeks. RESULTS: Fifty patients received ≥1 dose of epacadostat. As of January 20, 2017, 2 patients completed treatment and 48 discontinued, primarily because of adverse events (AEs) and disease progression (n = 20 each). Dose-limiting toxicities occurred in 11 patients (n = 1 each with epacadostat 25 mg BID, 50 mg BID intermittent, 75 mg daily; n = 4 each with epacadostat 50 mg BID, 300 mg BID). The most common immune-related treatment-emergent AEs included rash (50%), alanine aminotransferase elevation (28%), pruritus (28%), aspartate aminotransferase elevation (24%), and hypothyroidism (10%). Among immunotherapy-naive patients (n = 39), the objective response rate was 26% by immune-related response criteria and 23% by Response Evaluation Criteria in Solid Tumors version 1.1. No objective response was seen in the 11 patients who received prior immunotherapy. Epacadostat exposure was dose proportional, with clinically significant IDO1 inhibition at doses ≥25 mg BID. CONCLUSIONS: When combined with ipilimumab, epacadostat ≤50 mg BID demonstrated clinical and pharmacologic activity and was generally well tolerated in patients with advanced melanoma. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01604889 . Registration date, May 9, 2012, retrospectively registered.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf N26ac42922aca4237b3b6c979da7c3bf9
39 N73b42cc5b9ff4165b6f4f066dd6254a4
40 sg:journal.1049249
41 schema:name Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
42 schema:pagination 80
43 schema:productId Na26910ff4bf84ac1908b4cd66d94085c
44 Ncfd2792e397d4825a99de07d65a85b5f
45 Nd3b359fc434d4239b8d47ca92b332bba
46 Ne239dd4dc17c42ca98d903dc17700169
47 Ne5b86e6fa8294d1bae20f3d9415660c6
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112899763
49 https://doi.org/10.1186/s40425-019-0562-8
50 schema:sdDatePublished 2019-04-11T13:31
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher N1565a6c4b90e4c1eab804a7633a6820e
53 schema:url https://link.springer.com/10.1186%2Fs40425-019-0562-8
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N0012308a6b4f4e10bf0a82cd44ba85ac schema:affiliation https://www.grid.ac/institutes/grid.410396.9
58 schema:familyName Lutzky
59 schema:givenName Jose
60 rdf:type schema:Person
61 N01393887bcb34c7b89f6a8dd8c705f33 rdf:first Nfa29a42e5fb24d188165ca361056cd50
62 rdf:rest Ndaa5aae263e2415a8c3298822e1e6a7e
63 N125230fbb2764d4c996b2959b31a788d rdf:first N0012308a6b4f4e10bf0a82cd44ba85ac
64 rdf:rest N80e72958986d4679a8f51b3736dc9cde
65 N1565a6c4b90e4c1eab804a7633a6820e schema:name Springer Nature - SN SciGraph project
66 rdf:type schema:Organization
67 N26ac42922aca4237b3b6c979da7c3bf9 schema:volumeNumber 7
68 rdf:type schema:PublicationVolume
69 N29390be487e940eca5d7eb5dc5b5be6e rdf:first N8fe23bfc5be24a3e86efdfd9ae87ef43
70 rdf:rest N5a04ae6076904b9c828b7188f57a8760
71 N3782db677fd342c2ac0c1e975c7bfcb2 schema:affiliation https://www.grid.ac/institutes/grid.411115.1
72 schema:familyName Mitchell
73 schema:givenName Tara C.
74 rdf:type schema:Person
75 N476c683c81b34f97895af8b999958826 schema:affiliation https://www.grid.ac/institutes/grid.417921.8
76 schema:familyName Maleski
77 schema:givenName Janet
78 rdf:type schema:Person
79 N4f6fdf4235d84bbebd1103394d5ed5d1 schema:affiliation https://www.grid.ac/institutes/grid.412530.1
80 schema:familyName Olszanski
81 schema:givenName Anthony J.
82 rdf:type schema:Person
83 N5a04ae6076904b9c828b7188f57a8760 rdf:first N79bfce7dadca4c3e9432542e0bd7478d
84 rdf:rest N01393887bcb34c7b89f6a8dd8c705f33
85 N689ac75941944cb3b91f90fac61489b5 rdf:first Neb3ab0909c6c4da78404534c9d3a7713
86 rdf:rest N29390be487e940eca5d7eb5dc5b5be6e
87 N73b42cc5b9ff4165b6f4f066dd6254a4 schema:issueNumber 1
88 rdf:type schema:PublicationIssue
89 N7943064252d841b58587102187821996 schema:name Department of Hematology/Oncology, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL, USA
90 rdf:type schema:Organization
91 N79bfce7dadca4c3e9432542e0bd7478d schema:affiliation https://www.grid.ac/institutes/grid.417921.8
92 schema:familyName Zhao
93 schema:givenName Yufan
94 rdf:type schema:Person
95 N80e72958986d4679a8f51b3736dc9cde rdf:first N4f6fdf4235d84bbebd1103394d5ed5d1
96 rdf:rest N8963b39871d04a66bd1c8351ef47b121
97 N8963b39871d04a66bd1c8351ef47b121 rdf:first N3782db677fd342c2ac0c1e975c7bfcb2
98 rdf:rest Nc7d0c44066d842c096703e8bce862a16
99 N8fe23bfc5be24a3e86efdfd9ae87ef43 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
100 schema:familyName Hanks
101 schema:givenName Brent A.
102 rdf:type schema:Person
103 N923a9bf32e5a4e329d5593268c88f656 schema:affiliation https://www.grid.ac/institutes/grid.240324.3
104 schema:familyName Weber
105 schema:givenName Jeffrey S.
106 rdf:type schema:Person
107 Na26910ff4bf84ac1908b4cd66d94085c schema:name nlm_unique_id
108 schema:value 101620585
109 rdf:type schema:PropertyValue
110 Na596e9586af64dd99704238f097c28e6 schema:affiliation N7943064252d841b58587102187821996
111 schema:familyName Gajewski
112 schema:givenName Thomas F.
113 rdf:type schema:Person
114 Nb972ba1ed6824ac880e23afd8552fa61 rdf:first N923a9bf32e5a4e329d5593268c88f656
115 rdf:rest rdf:nil
116 Nc152e7a572cb4fcbae6283a068b78e4f schema:affiliation https://www.grid.ac/institutes/grid.411663.7
117 schema:familyName Gibney
118 schema:givenName Geoffrey T.
119 rdf:type schema:Person
120 Nc7d0c44066d842c096703e8bce862a16 rdf:first Na596e9586af64dd99704238f097c28e6
121 rdf:rest N689ac75941944cb3b91f90fac61489b5
122 Ncfd2792e397d4825a99de07d65a85b5f schema:name dimensions_id
123 schema:value pub.1112899763
124 rdf:type schema:PropertyValue
125 Nd04eaafec71342dbb511addae56085da rdf:first Nf2af6c45b2ab417d868281eb841ad361
126 rdf:rest Nb972ba1ed6824ac880e23afd8552fa61
127 Nd3b359fc434d4239b8d47ca92b332bba schema:name doi
128 schema:value 10.1186/s40425-019-0562-8
129 rdf:type schema:PropertyValue
130 Ndaa5aae263e2415a8c3298822e1e6a7e rdf:first N476c683c81b34f97895af8b999958826
131 rdf:rest Nd04eaafec71342dbb511addae56085da
132 Ne239dd4dc17c42ca98d903dc17700169 schema:name readcube_id
133 schema:value 9ae17cccc8d9657d682c59e3f1f732d13e0d9e9b0e1fd003473c149bdc131746
134 rdf:type schema:PropertyValue
135 Ne5b86e6fa8294d1bae20f3d9415660c6 schema:name pubmed_id
136 schema:value 30894212
137 rdf:type schema:PropertyValue
138 Neb3ab0909c6c4da78404534c9d3a7713 schema:affiliation https://www.grid.ac/institutes/grid.19006.3e
139 schema:familyName Chmielowski
140 schema:givenName Bartosz
141 rdf:type schema:Person
142 Nf2af6c45b2ab417d868281eb841ad361 schema:affiliation https://www.grid.ac/institutes/grid.417921.8
143 schema:familyName Leopold
144 schema:givenName Lance
145 rdf:type schema:Person
146 Nfa29a42e5fb24d188165ca361056cd50 schema:affiliation https://www.grid.ac/institutes/grid.417921.8
147 schema:familyName Newton
148 schema:givenName Robert C.
149 rdf:type schema:Person
150 Nfa6940ebb61c4c299d0a97de405aa14a rdf:first Nfdf0645be5ce4248b7d9ea48668d425e
151 rdf:rest N125230fbb2764d4c996b2959b31a788d
152 Nfdf0645be5ce4248b7d9ea48668d425e schema:affiliation https://www.grid.ac/institutes/grid.488730.0
153 schema:familyName Hamid
154 schema:givenName Omid
155 rdf:type schema:Person
156 Nfef5b798b6c34c90a79962c20d3dac03 rdf:first Nc152e7a572cb4fcbae6283a068b78e4f
157 rdf:rest Nfa6940ebb61c4c299d0a97de405aa14a
158 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
159 schema:name Medical and Health Sciences
160 rdf:type schema:DefinedTerm
161 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
162 schema:name Immunology
163 rdf:type schema:DefinedTerm
164 sg:journal.1049249 schema:issn 2051-1426
165 schema:name Journal for ImmunoTherapy of Cancer
166 rdf:type schema:Periodical
167 sg:pub.10.1038/nm934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015972513
168 https://doi.org/10.1038/nm934
169 rdf:type schema:CreativeWork
170 sg:pub.10.1186/2051-1426-2-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002294525
171 https://doi.org/10.1186/2051-1426-2-3
172 rdf:type schema:CreativeWork
173 sg:pub.10.1186/s40425-015-0094-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022743938
174 https://doi.org/10.1186/s40425-015-0094-9
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1002/ijc.28927 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039147819
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1016/j.cellimm.2014.02.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001542971
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1016/j.celrep.2015.08.077 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034973964
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1016/j.ejca.2011.09.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036514939
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1016/j.immuni.2013.07.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006498518
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1016/s0140-6736(14)60958-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012632588
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1016/s1470-2045(16)30366-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001468571
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1056/nejmoa1003466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052212829
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1056/nejmoa1305133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042841008
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1056/nejmoa1503093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014234053
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1056/nejmoa1504030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024843336
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1056/nejmra041867 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016818264
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1158/1078-0432.ccr-09-1624 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028571226
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1158/1078-0432.ccr-16-2272 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063225692
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1158/1535-7163.mct-09-0628 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044405906
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1158/2326-6066.cir-14-0137 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031443287
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1159/000492849 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106286757
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1172/jci21583 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041748772
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1172/jci31178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032110459
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1182/blood-2009-09-246124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009595417
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1200/jco.2018.36.15_suppl.108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106714265
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1371/journal.pone.0143080 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019103667
221 rdf:type schema:CreativeWork
222 https://doi.org/10.3109/10408363.2011.599831 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034859605
223 rdf:type schema:CreativeWork
224 https://doi.org/10.4049/jimmunol.1100164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033755558
225 rdf:type schema:CreativeWork
226 https://www.grid.ac/institutes/grid.189509.c schema:alternateName Duke University Hospital
227 schema:name Department of Medicine, Duke University Medical Center, 20 Duke Medicine Cir, Durham, NC, USA
228 rdf:type schema:Organization
229 https://www.grid.ac/institutes/grid.19006.3e schema:alternateName University of California Los Angeles
230 schema:name Jonsson Comprehensive Medical Center, University of California, Los Angeles, 10945 Le Conte Ave #2339, Los Angeles, CA, USA
231 rdf:type schema:Organization
232 https://www.grid.ac/institutes/grid.240324.3 schema:alternateName New York University Langone Medical Center
233 schema:name Donald A. Adam Melanoma and Skin Cancer Research Center of Excellence, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
234 Present Address: Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA
235 rdf:type schema:Organization
236 https://www.grid.ac/institutes/grid.410396.9 schema:alternateName Mount Sinai Medical Center
237 schema:name Division of Hematology & Oncology, Mount Sinai Medical Center, 4306 Alton Rd, Miami Beach, FL, USA
238 rdf:type schema:Organization
239 https://www.grid.ac/institutes/grid.411115.1 schema:alternateName Hospital of the University of Pennsylvania
240 schema:name Division of Hematology Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, USA
241 rdf:type schema:Organization
242 https://www.grid.ac/institutes/grid.411663.7 schema:alternateName MedStar Georgetown University Hospital
243 schema:name Donald A. Adam Melanoma and Skin Cancer Research Center of Excellence, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
244 Present Address: Lombardi Comprehensive Cancer Center, Medstar-Georgetown University Hospital, 3800 Reservoir Road NW, Podium A, 20007, Washington, DC, USA
245 rdf:type schema:Organization
246 https://www.grid.ac/institutes/grid.412530.1 schema:alternateName Temple University Health System
247 schema:name Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, USA
248 rdf:type schema:Organization
249 https://www.grid.ac/institutes/grid.417921.8 schema:alternateName Incyte (United States)
250 schema:name Incyte Corporation, 1801 Augustine Cutoff, Wilmington, DE, USA
251 rdf:type schema:Organization
252 https://www.grid.ac/institutes/grid.488730.0 schema:alternateName Angeles Clinic and Research Institute
253 schema:name Melanoma and Skin Cancers Center, The Angeles Clinic and Research Institute, 11818 Wilshire Blvd, Suite #200, Los Angeles, CA, USA
254 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...